Previous 10 | Next 10 |
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2021 Earnings Conference Call August 09, 2021 08:00 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Andy Boye...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
‒ Q2 2021 Net Revenue of $535 million; GAAP Net Income of $15 million; Diluted Income per Share of $0.10 ‒ ‒ Adjusted EBITDA (1) of $151 million; Adjusted Diluted EPS (1) of $0.25 ‒ ‒ Maintaining 2021 Full Year Financial Outlo...
AMRX,APD,AVYA,BALY,BHVN,BLUE,BNTX,CEVA,CRNC,DISH,EBIX,ELAN,ENR,EPZM,GOLD,GTES,KOD,RDNT,SGMS,SWAV,SYNH,TGNA,TSN,TTD,USFD,VTRS,VTR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
Pgiam/iStock via Getty Images Earnings reports dominated the headlines on Tuesday. IBM (IBM) and HCA Healthcare (HCA) both gained ground in pre-market action following their quarterly releases. PPG Industries (PPG) dropped following the announcement of its financial figures. There were also s...
RealPeopleGroup/E+ via Getty Images The FDA has approved an ANDA from Amneal Pharmaceuticals ([[AMRX]] +0.2%) for a generic of TobraDex (dexamethasone and tobramycin ophthalmic suspension).The drug is indicated for for steroid-responsive inflammatory ocular conditions.Sales of TobraDex f...
- Adding another complex ophthalmic product to the generics portfolio Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food an...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:00 a.m. Eastern ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many investors like cheap shares, particularly those under $10, and frequently put them on their lists of “stocks to watch.” After all, many of today’s market darlings were trading at much lower values ...
The global economic recovery can be attributed in large measure to the efforts of several healthcare companies in their race to develop a COVID-19 vaccine. With governments now pouring billions of dollars to further improve the healthcare industry, and companies in the sector focusing on meet...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...